Molecular and Clinical Characterization of Patients with Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.08.001 ◽

2021 ◽

Author(s):

Mark C. Markowski ◽

Sushant Kachhap ◽

Angelo M. De Marzo ◽

Laura A. Sena ◽

Jun Luo ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Androgen Therapy ◽

Castration Resistant

Download Full-text

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

The Prostate ◽

10.1002/pros.23955 ◽

2020 ◽

Vol 80 (5) ◽

pp. 407-411

Author(s):

Mark C. Markowski ◽

Eugene Shenderov ◽

Mario A. Eisenberger ◽

Sushant Kachhap ◽

Drew M. Pardoll ◽

...

Keyword(s):

Prostate Cancer ◽

Immune Checkpoint ◽

Immune Checkpoint Blockade ◽

Checkpoint Blockade ◽

Castration Resistant Prostate Cancer ◽

Androgen Therapy ◽

Castration Resistant ◽

Extreme Responses

Download Full-text

Faculty Opinions recommendation of Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732320563.793553396 ◽

2018 ◽

Author(s):

Michael Glode

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Androgen Therapy ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones

Human Cell ◽

10.1007/s13577-020-00435-6 ◽

2020 ◽

Vol 34 (1) ◽

pp. 211-218

Author(s):

Jacky K. Leung ◽

Teresa Tam ◽

Jun Wang ◽

Marianne D. Sadar

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Isolation And Characterization

Download Full-text

Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer

Journal of Medicinal Chemistry ◽

10.1021/acs.jmedchem.9b00327 ◽

2019 ◽

Vol 62 (9) ◽

pp. 4716-4730 ◽

Cited By ~ 13

Author(s):

Yan Zhang ◽

Xishan Wu ◽

Xiaoqian Xue ◽

Chenchang Li ◽

Junjian Wang ◽

...

Keyword(s):

Prostate Cancer ◽

Inverse Agonist ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Orally Bioavailable

Download Full-text

Abstract B107: Characterization of a small molecule selective androgen receptor downregulator: A novel approach for the treatment of castration-resistant prostate cancer.

10.1158/1535-7163.targ-11-b107 ◽

2011 ◽

Cited By ~ 1

Author(s):

Sarah A. Loddick ◽

Sandra Brave ◽

Hayley Campbell ◽

Luke Gaughan ◽

Jim Growcott ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Small Molecule ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Novel Approach

Download Full-text

Abstract A153: Isolation and characterization of high-purity invasive CTCs from men with metastatic castration-resistant prostate cancer (mCRPC).

10.1158/1535-7163.targ-13-a153 ◽

2013 ◽

Author(s):

Gayatri Premasekharan ◽

Terence W. Friedlander ◽

Vy T. Ngo ◽

Elizabeth Gilbert ◽

Priya Sathaye ◽

...

Keyword(s):

Prostate Cancer ◽

High Purity ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Isolation And Characterization

Download Full-text

Abstract 375: Phenotypic and molecular characterization of circulating tumor cells (CTCs) in patients with castration resistant prostate cancer (CRPC) undergoing treatment with abiraterone acetate or enzalutamide

10.1158/1538-7445.am2015-375 ◽

2015 ◽

Author(s):

Jaymala Patel ◽

Vipul Bhargava ◽

Miaoling He ◽

Brad Foulk ◽

Denis A. Smirnov ◽

...

Keyword(s):

Prostate Cancer ◽

Tumor Cells ◽

Molecular Characterization ◽

Circulating Tumor Cells ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Abstract 1114: Combining anti-androgen therapy and PARP inhibition results in synergistic cytotoxicity of metastatic castration-resistant prostate cancer (mCRPC) cells

10.1158/1538-7445.am2017-1114 ◽

2017 ◽

Author(s):

Sahithi Pamarthy ◽

Vinay Sagar ◽

Rajita J. Vatapalli ◽

Zachary Reinstein ◽

Muhammad Zayd Ansari ◽

...

Keyword(s):

Prostate Cancer ◽

Parp Inhibition ◽

Castration Resistant Prostate Cancer ◽

Androgen Therapy ◽

Castration Resistant ◽

Synergistic Cytotoxicity

Download Full-text

1.5-Year Posttreatment Follow-Up of Radium-223 Dichloride (Ra-223) Safety in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases from Alsympca: Characterization of Hematologic Safety Profiles

Annals of Oncology ◽

10.1093/annonc/mdu336.17 ◽

2014 ◽

Vol 25 ◽

pp. iv263

Author(s):

C. Parker ◽

N. Vogelzang ◽

O. Sartor ◽

D. Bottomley ◽

R.E. Coleman ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Radium 223

Download Full-text

A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e16080 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e16080-e16080

Author(s):

Edwin M. Posadas ◽

Mourad Tighgohart ◽

YI-TSUNG LU ◽

Dolores Di Vizio ◽

David M. J. Hoffman ◽

...

Keyword(s):

Prostate Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Phase 2 Study ◽

Visceral Metastases

Download Full-text